Vincerx Pharma, Inc. (VINC)
USD 0.22
(12.97%)
USD 0.22
(12.97%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | 915 Thousand | 939 Thousand | 340 Thousand | 172.99 Thousand | 172.99 Thousand |
| Gross Profit | -915 Thousand | -939 Thousand | -340 Thousand | -172.99 Thousand | -172.99 Thousand |
| Operating Expenses | 42.6 Million | 71.1 Million | 62.65 Million | 10.71 Million | 45 Thousand |
| Selling, General and Administrative Expenses | 13.63 Million | 18.95 Million | 22.57 Million | 3.59 Million | 45 Thousand |
| Research and Development Expenses | 28.97 Million | 52.15 Million | 40.08 Million | 7.11 Million | - |
| Other Expenses | - | 1.24 Million | -8000.00 | -8000.00 | - |
| Cost and Expenses | 42.6 Million | 71.1 Million | 62.65 Million | 10.71 Million | 45 Thousand |
| Operating Income | -42.6 Million | -73.57 Million | -62.65 Million | -10.71 Million | -45 Thousand |
| Interest Expense | - | - | - | 8000.00 | - |
| Income Tax Expense | - | -8.2 Million | -23.69 Million | 8000.00 | -54.00 |
| Earnings before Tax | -40.15 Million | -65.36 Million | -39.3 Million | -10.72 Million | -45 Thousand |
| Net Income | -40.15 Million | -57.16 Million | -15.6 Million | -10.73 Million | -45 Thousand |
| Earnings Per Share Basic | -1.89 | -2.72 | -0.91 | -0.77 | -0.01 |
| Earnings Per Share Diluted | -1.89 | -2.72 | -0.91 | -0.77 | -0.01 |
| Weighted Average Shares Outstanding | 21.29 Million | 21.02 Million | 17.17 Million | 13.98 Million | 5.19 Million |
| Weighted Average Shares Outstanding (Diluted) | 21.29 Million | 21.02 Million | 17.17 Million | 13.98 Million | 5.19 Million |
| Gross Margin | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - |
| Profit Margin | - | - | - | - | - |
| EBITDA | -42.6 Million | -68.66 Million | -62.65 Million | -10.71 Million | 9000.00 |
| Earnings Before Tax Margin | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 1.31 Million | - | - |
| Cost of Revenue | 270 Thousand | 264 Thousand | 915 Thousand | 258 Thousand | 254 Thousand | 249 Thousand |
| Gross Profit | -270 Thousand | -264 Thousand | -915 Thousand | 1.05 Million | -254 Thousand | -249 Thousand |
| Operating Expenses | 7.09 Million | 7.21 Million | 41.69 Million | 5.27 Million | 10.31 Million | 11.66 Million |
| Selling, General and Administrative Expenses | 3.61 Million | 2.92 Million | - | 1.82 Million | 3.51 Million | 3.78 Million |
| Research and Development Expenses | 3.48 Million | 4.29 Million | - | 3.45 Million | 6.8 Million | 7.87 Million |
| Other Expenses | 138 Thousand | 154 Thousand | - | 444 Thousand | 230 Thousand | 300 Thousand |
| Cost and Expenses | 7.36 Million | 7.47 Million | 42.6 Million | 5.53 Million | 10.31 Million | 11.66 Million |
| Operating Income | -7.36 Million | -7.47 Million | -42.6 Million | -5.53 Million | -10.31 Million | -11.66 Million |
| Interest Expense | - | - | - | 758 Thousand | - | - |
| Income Tax Expense | - | 220.72 Thousand | - | 1.58 Million | -372 Thousand | -458 Thousand |
| Earnings before Tax | -1.8 Million | -12.42 Million | -40.15 Million | -4.95 Million | -9.71 Million | -11.15 Million |
| Net Income | -1.8 Million | -12.42 Million | -40.15 Million | -4.95 Million | -9.71 Million | -11.15 Million |
| Earnings Per Share Basic | -0.05 | -0.58 | - | -0.23 | -0.46 | -0.52 |
| Earnings Per Share Diluted | -0.05 | -0.58 | - | -0.23 | -0.46 | -0.52 |
| Weighted Average Shares Outstanding | 38.33 Million | 21.4 Million | 21.29 Million | 21.4 Million | 21.34 Million | 21.27 Million |
| Weighted Average Shares Outstanding (Diluted) | 38.33 Million | 21.4 Million | 21.29 Million | 21.4 Million | 21.34 Million | 21.27 Million |
| Gross Margin | - | - | - | 0.80 | - | - |
| EBIT Margin | - | - | - | -4.01 | - | - |
| Profit Margin | - | - | - | -3.77 | - | - |
| EBITDA | -7.09 Million | -7.21 Million | - | -5.27 Million | -10.17 Million | -11.54 Million |
| Earnings Before Tax Margin | - | - | - | -4.21 | - | - |
300126
MDVT
IAG
NOM
EAATF
ATRL